MicroRNA-33a and microRNA-33b are encoded within the mammalian SREBF1 and SRBF2 genes, respectively, and both SREBF1 and ...

Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

So, the first JAK inhibitor came to market with the promise of getting oral efficacy, where previously it was injectable or infusible.

Phenotypic cell-based screening is a powerful approach to small-molecule discovery, but a major challenge of this strategy lies in determining the intracellular target and mechanism of action (MoA) ...

Panelists discuss how clinical trial data has shaped second-line therapy in polycythemia vera (PV), highlighting ruxolitinib and interferon as key options for patients resistant or intolerant to ...

Objectives To compare the incidence of cardiovascular (CV) events in rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or other ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis ...